IGF-1 LR3

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is IGF-1 LR3?

IGF-1 LR3 — sometimes written as IGF 1 LR3, Long R3 IGF-1, or LR3IGF-I — is a synthetic analog of human insulin-like growth factor 1. The name itself describes two specific structural modifications:

• “Long” — a 13-amino-acid N-terminal extension peptide added to the native IGF-1 sequence.
• “R3” — a substitution of glutamic acid (Glu) with arginine (Arg) at position 3 of the mature IGF-1 sequence.

Together, these modifications produce an 83-amino-acid peptide (versus 70 for native IGF-1) with the molecular formula C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉, a molecular weight of approximately 9,111 g/mol, and CAS number 946870-92-4.[2] The critical functional consequence: IGF-1 LR3 binds very poorly to the six known IGFBPs that normally sequester and regulate endogenous IGF-1 in circulation.[1][7][8] This is the single most important distinction between LR3 and the native growth factor.

The original characterisation of these IGF-1 analogs — including the Arg3 substitution — was published by King, Francis, and colleagues in 1992, who demonstrated that reduced IGFBP binding rather than enhanced receptor affinity explained the increased potency of these variants.[2]

Compound Profile

Mechanism of Action

The IGF-1 mechanism centres on activation of the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally related to the insulin receptor. When IGF-1 LR3 binds the IGF-1R, it triggers receptor autophosphorylation and activation of two primary downstream cascades:[4]

• PI3K/Akt/mTOR pathway — drives protein synthesis, cell survival (anti-apoptotic signalling), and glucose uptake. This is the primary anabolic signalling axis relevant to muscle hypertrophy research.
• Ras/MAPK/ERK pathway — promotes cell proliferation and differentiation, with important implications for both tissue growth and proliferative risk.

Laviola et al. (2007) provided a comprehensive review of IGF-I signal transduction, noting that IGF-1R activation leads to tyrosine phosphorylation of multiple substrates including IRS proteins and Shc, ultimately responsible for cell proliferation, tissue differentiation modulation, and protection from apoptosis.[4] These pathways operate identically whether activated by native IGF-1 or the LR3 variant — the difference is duration and magnitude of exposure, not the downstream signalling itself.

Critically, IGF-1 acts through both endocrine (circulating) and autocrine/paracrine (locally produced) mechanisms. Endogenous IGF-1 is primarily produced by the liver in response to growth hormone (GH) stimulation, but skeletal muscle, bone, and other tissues also produce IGF-1 locally.[5][6] The IGF-1 LR3 variant bypasses the normal regulatory checkpoints that limit how long circulating IGF-1 remains bioactive.

Why LR3? The IGFBP Problem

Understanding why LR3 was engineered requires understanding the IGFBP system. In normal physiology, approximately 98% of circulating IGF-1 is bound to one of six IGF binding proteins (IGFBP-1 through IGFBP-6). The majority exists in a 150 kDa ternary complex with IGFBP-3 and the acid-labile subunit (ALS).[6][7][8]

This binding serves several functions:

• Extends half-life — free IGF-1 has a half-life of approximately 10–12 minutes; IGFBP-bound IGF-1 persists for hours.
• Controls bioavailability — only free (unbound) IGF-1 can activate the IGF-1R.
• Provides tissue-specific regulation — different IGFBPs are expressed in different tissues, creating localised control of IGF-1 action.

Bach (2015) and Forbes et al. (2012) reviewed the structural basis of IGFBP function extensively, demonstrating that these binding proteins act as both reservoirs and regulators of IGF bioactivity.[7][8] The system is elegant: it prevents uncontrolled IGF-1R activation while maintaining a large circulating reservoir that can be released locally through IGFBP proteolysis.

The LR3 modification effectively circumvents this entire regulatory system. By dramatically reducing IGFBP affinity, Long R3 IGF-1 remains in its free, bioactive form for far longer — producing the extended ~20–30 hour half-life that distinguishes it from native IGF-1.[1][2] This is simultaneously what makes it a useful research tool and what raises significant safety concerns: the normal braking system for IGF-1 signalling is largely removed.

Muscle & Hypertrophy Research

The anabolic potential of IGF-1 LR3 has been the primary driver of research interest. The foundational study by Tomas et al. (1993) demonstrated that LR3IGF-I was substantially more potent than native IGF-1 in promoting anabolic effects in rats — a daily dose of 44 μg/day of the LR3 variant produced effects comparable to 278 μg/day of native IGF-1 (roughly 6-fold greater potency).[1] Effects included increased body weight gain, improved nitrogen retention, greater food conversion efficiency, and increased muscle protein synthesis.

At the cellular level, IGF-1 signalling through PI3K/Akt/mTOR promotes:

• Satellite cell activation and proliferation — key to muscle fibre repair and hypertrophy.
• Increased protein synthesis — via mTOR-mediated translation initiation.
• Reduced protein degradation — through inhibition of the ubiquitin-proteasome pathway.

Philippou et al. (2007) reviewed the role of IGF-1 isoforms in skeletal muscle physiology, highlighting that locally expressed, mechanically sensitive IGF-1 isoforms regulate the competing processes of cellular proliferation and differentiation required for muscle repair and hypertrophy.[3] Xi et al. (2004) specifically examined Long-R3-IGF-I effects on L6 myogenic cells, demonstrating that IGFBP-3 suppresses both IGF-I and Long-R3-IGF-I-stimulated proliferation — providing important mechanistic data on how the IGFBP bypass operates at the cellular level.[9]

However, a critical caveat: the Tomas et al. study and most subsequent research used animal models. There are no published controlled human trials specifically examining IGF-1 LR3 for muscle hypertrophy outcomes. The translation gap between rat anabolism data and human physiology remains significant.

Metabolic & Body Composition Effects

Beyond direct anabolic effects, IGF-1 signalling influences broader metabolic pathways relevant to body composition. Clemmons (2012) reviewed the metabolic actions of IGF-I, noting that it stimulates protein synthesis in muscle while also promoting free fatty acid utilisation and enhancing insulin sensitivity.[5] These properties suggest a nutrient-partitioning effect — directing calories toward lean tissue rather than fat storage.

Key metabolic actions associated with IGF-1R activation include:

• Glucose uptake — IGF-1 can stimulate glucose transport through a mechanism partially overlapping with insulin signalling.
• Fatty acid oxidation — promotion of fat as a fuel substrate.
• Protein synthesis prioritisation — enhanced nitrogen retention observed in animal models.[1][5]

Conlon et al. (1995) infused Long R3 IGF-I into guinea pigs and observed organ growth effects but no significant changes in body weight, feed intake, or carcass composition — though the study did note that LR3IGF-I reduced endogenous IGF-I, IGF-II, and IGFBP concentrations, suggesting negative feedback effects.[10] This is an important finding: exogenous IGF-1 LR3 may suppress the body’s own IGF system, and the net metabolic impact is not straightforwardly additive.

The metabolic evidence for IGF-1 LR3 specifically remains limited. Most understanding is extrapolated from endogenous IGF-1 physiology and clinical studies using recombinant human IGF-1 (mecasermin) in conditions like severe insulin resistance.[5]

Side Effects & Safety Concerns

The IGF-1 side effects profile — and IGF-1 LR3 side effects specifically — demands honest discussion. Because LR3 removes the normal IGFBP regulatory brake on IGF-1 signalling, several serious concerns emerge:

Hypoglycaemia

IGF-1 has insulin-like metabolic effects, including glucose uptake stimulation. Clemmons (2012) noted that patients receiving IGF-1 are sensitive to hypoglycaemic side effects.[5] The extended bioavailability of LR3 may prolong this risk window.

Organ Growth (Organomegaly)

Both Tomas et al. (1993) and Conlon et al. (1995) observed organ weight changes in animals receiving IGF-1 analogs.[1][10] Sustained IGF-1R activation promotes cell growth across all tissues — not selectively in skeletal muscle. Gut, heart, kidney, and other organs may respond to prolonged IGF-1 signalling.

Proliferative and Cancer Risk

This is the most significant safety concern. The PI3K/Akt/mTOR and Ras/MAPK pathways activated by IGF-1R are the same pathways implicated in tumour cell survival and proliferation.[4][6] Yakar et al. (2002) explicitly noted the role of IGF-I in cancer biology.[6] Epidemiological studies have linked higher circulating IGF-1 levels with increased risk of certain cancers. While correlation does not establish causation, the mechanistic logic is clear: sustained, unregulated IGF-1R activation promotes cell survival and proliferation — precisely the conditions that favour tumour growth. This risk is not theoretical; it is a direct and predictable consequence of the mechanism of action.

WADA Prohibition

IGF-1 LR3 is classified under WADA’s S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is prohibited at all times, both in-competition and out-of-competition, in all WADA-governed sports.

Suppression of Endogenous IGF System

Conlon et al. (1995) demonstrated that LR3IGF-I infusion reduced plasma concentrations of endogenous IGF-I, IGF-II, and IGF binding proteins.[10] This suggests negative feedback suppression of the body’s own growth factor system — a consideration for any research protocol.

Half-Life & Pharmacokinetics

The pharmacokinetic profile of IGF-1 LR3 is defined almost entirely by its IGFBP bypass mechanism. Native IGF-1 in its free form has a half-life of approximately 10–12 minutes — extremely short. However, when bound in the 150 kDa ternary complex (IGF-1 + IGFBP-3 + ALS), the effective half-life extends to 12–15 hours.[6][7]

IGF-1 LR3 achieves an estimated half-life of ~20–30 hours through the opposite mechanism: rather than being stabilised by binding proteins, it simply avoids being bound in the first place. This means it circulates in its free, bioactive form for extended periods.[1][2] The practical consequence is prolonged, relatively constant IGF-1R activation — in contrast to the pulsatile, IGFBP-regulated pattern of endogenous IGF-1 signalling.

This pharmacokinetic profile explains both the enhanced potency observed in animal studies and the safety concerns: normal IGF-1 signalling is tightly regulated in amplitude and duration; LR3 removes both of those constraints.

FAQ

What is IGF-1 LR3 and how does it differ from regular IGF-1?

IGF-1 LR3 is a modified 83-amino-acid analog of the natural 70-amino-acid insulin-like growth factor 1. The “Long” refers to a 13-amino-acid N-terminal extension, and “R3” refers to an arginine substitution at position 3. These modifications drastically reduce binding to IGF binding proteins (IGFBPs), extending the half-life from minutes (free IGF-1) to approximately 20–30 hours. The IGF-1 LR3 peptide activates the same receptor as native IGF-1 but remains bioactive for much longer.[1][2]

What are the IGF-1 LR3 benefits studied in research?

The primary IGF-1 LR3 benefits investigated in preclinical research include increased protein synthesis, enhanced nitrogen retention, satellite cell activation relevant to muscle hypertrophy, and nutrient-partitioning effects. Tomas et al. (1993) demonstrated approximately 6-fold greater anabolic potency compared to native IGF-1 in rat models.[1] However, these IGF-1 benefits have not been confirmed in controlled human trials for the LR3 variant specifically.

What are the known IGF-1 LR3 side effects?

Documented IGF-1 LR3 side effects in preclinical research include hypoglycaemia, organ growth (organomegaly), suppression of endogenous IGF system components, and theoretical proliferative/cancer risk from sustained IGF-1R activation.[1][5][6][10] The IGF-1 side effects profile for LR3 is potentially more pronounced than for native IGF-1 due to the extended half-life and lack of IGFBP regulation.

Is IGF-1 LR3 approved for human use?

No. IGF-1 LR3 is not FDA-approved and is not approved by any regulatory agency for human therapeutic use. It is classified as a research compound. Recombinant human IGF-1 (mecasermin/Increlex) is FDA-approved for severe primary IGF-1 deficiency, but that is the native 70-amino-acid peptide — not the LR3 variant.

How does IGF-1 LR3 compare to GH secretagogues for muscle growth research?

GH secretagogues (e.g., CJC-1295, ipamorelin) work upstream by stimulating natural GH release, which then increases endogenous IGF-1 through regulated pathways. IGF-1 LR3 works downstream, delivering a modified growth factor that bypasses normal regulation. GH secretagogues preserve physiological feedback loops; IGF-1 LR3 circumvents them. The human safety evidence is substantially stronger for GH secretagogues.

Is IGF-1 LR3 banned in sport?

Yes. IGF-1 LR3 is prohibited at all times by the World Anti-Doping Agency (WADA) under category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. This applies to all WADA-governed sports, both in-competition and out-of-competition.

What is the cancer risk associated with IGF-1 signalling?

Sustained IGF-1R activation promotes cell survival and proliferation through PI3K/Akt/mTOR and Ras/MAPK pathways — the same pathways implicated in tumour biology.[4][6] Epidemiological data associate higher circulating IGF-1 with increased risk of certain cancers. While the LR3 variant has not been studied specifically in this context, its mechanism of extended, unregulated IGF-1R activation is consistent with elevated proliferative risk. This is a genuine concern, not a theoretical one.

How strong is the evidence for IGF-1 LR3 specifically?

Evidence confidence for IGF-1 LR3 is limited. The literature is dominated by in vitro cell culture studies and animal models.[1][9][10] Most human IGF-1 research uses the native peptide (mecasermin) rather than the LR3 variant. Extrapolating from endogenous IGF-1 biology is reasonable but not equivalent to direct evidence. Any interpretation should weight this translation gap appropriately.

References

1. Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. PMID: 8371075. PubMed.
2. King R, Wells JR, Krieg P, Snoswell M, Brazier J, Bagley CJ, Wallace JC, Ballard FJ, Ross M, Francis GL. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3. J Mol Endocrinol. 1992;8(1):29-41. PMID: 1311930. PubMed.
3. Philippou A, Halapas A, Maridaki M, Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo. 2007;21(1):45-54. PMID: 17354613. PubMed.
4. Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des. 2007;13(7):663-669. PMID: 17346182. PubMed.
5. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41(2):425-443. PMID: 22682639. PubMed.
6. Yakar S, Wu Y, Setser J, Rosen CJ. The role of circulating IGF-I: lessons from human and animal models. Endocrine. 2002;19(3):239-248. PMID: 12624423. PubMed.
7. Bach LA. Insulin-like growth factor binding proteins 4-6. Best Pract Res Clin Endocrinol Metab. 2015;29(5):713-722. PMID: 26522456. PubMed.
8. Forbes BE, McCarthy P, Norton RS. Insulin-like growth factor binding proteins: a structural perspective. Front Endocrinol (Lausanne). 2012;3:38. PMID: 22654863. PubMed.
9. Xi G, Kamanga-Sollo E, Pampusch MS, White ME, Hathaway MR, Dayton WR. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. J Cell Physiol. 2004;200(3):387-394. PMID: 15254966. PubMed.
10. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-253. PMID: 7561636. PubMed.